Johnson & Johnson’s (J&J’s) Zytiga (abiraterone acetate), a drug used for prostate cancer, has significantly decreased the progression of the disease in men who have not started the chemotherapy as they are not in the advanced stages of cancer.
[hana-code-insert name=’StumbleUpon’ /][hana-code-insert name=’Reddit’ /]Zytiga was initially approved for use in patients who have already started the chemotherapy including the drug Taxotere.
J&J has reported that the results were positive in April after the announcement by an independent committee that the usage of placebo is no longer ethical. J&J is going to release the full results at the annual meeting of the American Society of Clinical Oncology in Chicago.
Clinical trial was done on 1,088 patients and the researchers found that the patients who received a combination of Zytiga and the steroid prednisone showed 57% less chances of advancement of cancer. Moreover, the combination also delayed the need for opiates and the use of chemotherapy. 25% decreased risk of death has been observed at any given moment in the study.
“These results are very promising for abiraterone acetate in the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic and have not received chemotherapy. The results also advance our understanding of the role of androgen biosynthesis inhibition in this patient population,” said Charles J. Ryan, M.D., lead investigator of the study and Associate Professor of Clinical Medicine at the UCSF Helen Diller Family Comprehensive Cancer Center. “This is an important study with all clinically relevant endpoints favoring treatment with abiraterone acetate plus prednisone, and is also the first to suggest that inhibiting androgen production significantly delays initiation of cytotoxic chemotherapy.”
Side effects include heart problems, fatigue, high blood pressure, and elevations of liver enzymes.
Via: Forbes Source: J&J